The AI Neurology & CNS Research Intelligence agent — synapse to circuit to patient.
A scientific research agent (not a chatbot, not a diagnostic tool) that discovers, connects, analyses, challenges and synthesises neuroscience & CNS knowledge from authorized literature, databases, datasets and enterprise tools — to help you understand what is known, what is unknown, what may be true, what has failed and what to test next.
Twelve deeply-connected knowledge domains spanning the research lifecycle.
Alzheimer's & dementias, Parkinson's & movement disorders, epilepsy, multiple sclerosis, ALS, stroke, migraine, neuropathic pain, and neurodevelopmental & psychiatric overlap across the lifespan.
Neuronal & glial biology, synaptic transmission, neuroinflammation, proteinopathies (amyloid, tau, α-synuclein, TDP-43), myelination, excitotoxicity, neurotrophic signalling and neural circuit dynamics.
Genomics (GWAS, rare variants, PRS), single-cell & spatial transcriptomics of brain regions, proteomics/CSF proteomics, metabolomics and epigenomics — connected gene → cell → circuit → phenotype.
Functional & structural connectivity, neuroimaging (MRI/PET/EEG/MEG), network degeneration patterns and brain–behaviour mapping — with methodological limits and reproducibility made explicit.
Human-genetic, functional, animal and multi-omics evidence for CNS targets — with tractability, brain expression, safety and prior program failures (a famously hard therapeutic area) clearly separated.
Small molecules, biologics, ASOs & RNA, gene therapy and cell therapy — plus the blood–brain-barrier delivery problem: CNS penetration, transport, intrathecal routes and shuttle technologies.
Diagnostic, prognostic, predictive and PD biomarkers across CSF/plasma (Aβ42/40, p-tau, NfL), PET tracers, digital & wearable measures — with performance, validation and clinical-utility context.
Design, population, endpoints (cognitive/functional scales, relapse rate, seizure frequency), biomarkers, comparators, results and adverse events — surfacing failed hypotheses and design opportunities.
CNS-specific toxicities, ARIA, seizure liability, suicidality signals, adherence and real-world effectiveness — distinguishing a signal from confirmed causality.
Longitudinal decline modelling, disease-progression & survival analysis, imaging analytics, causal inference and multi-omics integration on authorized neuroscience datasets.
Reasons across Disorder ↔ Gene ↔ Variant ↔ Protein ↔ Cell ↔ Circuit ↔ Biomarker ↔ Target ↔ Drug ↔ Trial ↔ Outcome, with every claim traceable to primary sources.
Finds conflicting findings, unexplained neurodegeneration mechanisms, missing biomarkers, poorly-validated targets and translational gaps — then frames testable hypotheses and experiments.
Surface novel, testable research directions and drug-repurposing leads across the whole ecosystem — not a single paper.
Integrate literature, omics, trials and real-world data into one traceable evidence graph so hidden connections become visible.
A built-in scientific critic tests for confounding, batch effects, power, publication bias, replication and prior failures.
Research questions, proposals, protocols, SAPs, reviews and manuscript scaffolds — never fabricating data, patients, stats or citations.
Statements are tagged so you always know their standing — and confidence is stated, never inflated. Citations, DOIs, PMIDs, dataset and trial IDs are drawn from primary sources; if a source can't be verified it says so. Neuro Genius is a research-intelligence system, not a substitute for a physician — it does not diagnose or treat individuals.
We use cookies to run Anxya Health and improve your experience. Choose how we may use them. Read our Cookie Policy, Privacy Policy and Terms.